header
Take the quiz

TAKE THE QUIZ

TEST YOUR KNOWLEDGE OF GPP

How much do you know about generalized pustular psoriasis (GPP)? Take this quiz to find out.

1. GPP is a chronic, neutrophilic skin disease characterized by EPISODES OF WIDESPREAD ERUPTIONS OF1,2

Required.

CORRECT!

GPP is characterized by recurring or persistent episodes of sterile, macroscopically visible pustules.1,3 These pustules are necessary to diagnose a GPP flare.4

NOT QUITE

GPP is characterized by recurring or persistent episodes of sterile, macroscopically visible pustules.1,3 These pustules are necessary to diagnose a GPP flare.4

2. Which of these is NOT a trigger of GPP?

Required.

CORRECT!

Stress, infections, and certain medications are all triggers of GPP.4 Acute myocardial events are not.

NOT QUITE

Stress, infections, and certain medications are all triggers of GPP.4 Acute myocardial events are not.

3. Which of these is a symptom of GPP?

Required.

NOT QUITE

Pustules, itching, burning sensation, and fever are all symptoms of GPP.4,5

CORRECT!

Pustules, itching, burning sensation, and fever are all symptoms of GPP.4,5

4. GPP FLARES ALWAYS OCCUR IN CONJUNCTION WITH PLAQUE PSORIASIS.

Required.

NOT QUITE

GPP flares can occur with or without plaque psoriasis.1

CORRECT!

GPP flares can occur with or without plaque psoriasis.1

5. The pathway that plays a key role in the pathogenesis of GPP is

Required.

NOT QUITE

The IL-36 pathway is a key driver of GPP.6

CORRECT!

The IL-36 pathway is a key driver of GPP.6

6. Which of the following statements about the economic burden of GPP vs Plaque Psoriasis is correct?

Required.

CORRECT!

Patients with GPP have higher rates of comorbidities than those with plaque psoriasis.7,8

NOT QUITE

Patients with GPP have higher rates of comorbidities than those with plaque psoriasis.7,8

7. Which of these is a comorbidity of GPP?

Required.

NOT QUITE

Common comorbidities in GPP include metabolic disorders, such as hyperlipidemia, obesity, hypertension, and diabetes mellitus.8

CORRECT!

Common comorbidities in GPP include metabolic disorders such as hyperlipidemia, obesity, hypertension,
and diabetes mellitus.8

8. In the differential diagnosis of GPP, the major diagnosis to exclude is

Required.

NOT QUITE

In diagnosing GPP, the major diagnosis to exclude is AGEP. Clinically, it may be almost impossible to distinguish AGEP from GPP.9

CORRECT!

In diagnosing GPP, the major diagnosis to exclude is AGEP. Clinically, it may be almost impossible to distinguish AGEP from GPP.9

9. Which of the following statements about the impact of GPP on quality of life is correct?

Required.

NOT QUITE

GPP has been shown to have a greater effect on quality of life than plaque psoriasis. A recent study using the CorEvitas Psoriasis Registry showed that patients with GPP reported more pain, itching, and fatigue compared with patients with plaque psoriasis.7

CORRECT!

GPP has been shown to have a greater effect on quality of life than plaque psoriasis. A recent study using the CorEvitas Psoriasis Registry showed that patients with GPP reported more pain, itching, and fatigue compared with patients with plaque psoriasis.7

10. Left untreated, GPP can lead to life-threatening complications.4,10 Which of the following complications are associated with GPP?

Required.

CORRECT!

ARDS, renal failure, and sepsis are all life-threatening complications associated with GPP.10

NOT QUITE

ARDS, renal failure, and sepsis are all life-threatening complications associated with GPP.10

IL-17=interleukin-17; IL-18=interleukin-18; IL-23=interleukin-23; IL-36=interleukin-36.

REFERENCES

  1. Navarini AA, Burden AD, Capon F, et al; for the ERASPEN Network. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. doi:10.1111/jdv.14386

  2. Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization diseases: an emerging concept encompassing various inflammatory keratinization disorders of the skin. J Dermatol Sci. 2018;90(2):105-111. doi:10.1016/j.jdermsci.2018.01.012

  3. Rivera-Díaz R, Daudén E, Carrascosa JM, Cueva P, Puig L. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment. Dermatol Ther (Heidelb). 2023;13(3):673-688. doi:10.1007/s13555-022-00881-0

  4. Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529-541. doi:10.1007/s13555-021-00493-0

  5. Skalicky A, Rentz A, Esser D, Thoma C, Gloede T. Symptom experience of patients with generalized pustular psoriasis (GPP). Value in Health. 2020;23(suppl 1):S345. Abstract: PRO89. doi:10.1016/j.jval.2020.04.1310

  6. Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109-120. doi:10.1016/j.jaci.2016.08.056

  7. Lebwohl M, Medeiros RA, Mackey RH, et al. The disease burden of generalized pustular psoriasis: real-world evidence from CorEvitas’ Psoriasis Registry. J Psoriasis Psoriatic Arthritis. 2022;7(2):71-78. doi:10.1177/24755303221079814

  8. Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252. doi:10.1080/1744666X.2019.1708193

  9. Sussman M, Napodano A, Huang S, Are A, Hsu S, Motaparthi K. Medicina (Kaunas). 2021;57(10):1004. doi:10.3390/medicina57101004

  10. Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37-42. doi:10.2147/PTT.S181808